ロード中...
Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report
INTRODUCTION: Platinum-resistant ovarian cancer is characterized by its poor prognosis and limited treatment options. Angiogenesis plays a fundamental role in the development of drug-resistance in ovarian cancer. Anlotinib, a novel oral multi-targeted tyrosine kinase inhibitor which targets a board...
保存先:
| 出版年: | Medicine (Baltimore) |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wolters Kluwer Health
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7253621/ https://ncbi.nlm.nih.gov/pubmed/32443311 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000020053 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|